Claims
- 1. An aerosol dispersion formulation comprising (i) a hydrogen-containing fluorocarbon or a hydrogen-containing chlorofluorocarbon propellant; (ii) a co-solvent having higher polarity than said propellant, which co-solvent is present in an amount of less than 1% w/w based upon the weight of the propellant; and (iii) a pre-coated medicament in an amount of from 0.005 to 5% w/w, based upon the total weight of the formulation, said pre-coated medicament consisting of a medicament in particulate form, said medicament having a particle size of less than 100 microns and having a dry surface coating of surfactant, which surfactant is present in an amount of from 0.01 to 10% w/w based upon the weight of the medicament and which surfactant has no affinity for said propellant.
- 2. A formulation as claimed in claim 1 wherein the propellant comprises 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane.
- 3. A formulation as claimed in claim 1 wherein the propellant comprises 1,1,1,2-tetrafluoroethane.
- 4. A formulation as claimed in claim 1 which contains less than 1% w/w, based upon the hydrogen-containing fluorocarbon or the hydrogen-containing chlorofluorocarbon propellant, of chlorofluorocarbons.
- 5. A formulation as claimed in claim 4 which contains less than 0.5% w/w of chlorofluorocarbons.
- 6. A formulation as claimed in claim 4 which contains 0.1% w/w or less of chlorofluorocarbons.
- 7. A formulation as claimed in claim 1 wherein the cosolvent is an aliphatic alcohol or a polyol.
- 8. A formulation as claimed in claim 7 wherein the cosolvent is ethanol.
- 9. A formulation as claimed in claim 1 which contains 0.05 to 3.0% w/w of cosolvent.
- 10. A formulation as claimed in claim 1 wherein the surfactant is selected from the group consisting of benzalkonium chloride, lecithin, oleic acid and sorbitan trioleate.
- 11. A formulation as claimed in claim 1 wherein the medicament is selected from the group consisting of salbutamol, salmeterol, beclomethasone esters and fluticasone esters.
- 12. A formulation as claimed in claim 1 wherein the medicament is salmeterol or a physiologically acceptable salt thereof.
- 13. A formulation as claimed in claim 1 wherein the medicament is salmeterol in the form of its hydroxynaphthoate salt.
- 14. A formulation as claimed in claim 13 wherein the propellant is 1,1,1,2-tetrafluoroethane.
- 15. A formulation as claimed in claim 14 wherein the surfactant is lecithin.
- 16. A formulation as claimed in claim 1 wherein the medicament is fluticasone propionate.
- 17. A formulation as claimed in claim 16 wherein the propellant is 1,1,1,2-tetrafluoroethane.
- 18. A formulation as claimed in claim 17 wherein the surfactant is lecithin.
- 19. A formulation as claimed in claim 1 wherein the medicament is salbutamol or a physiologically acceptable salt thereof.
- 20. A formulation as claimed in claim 19 wherein the medicament is salbutamol sulphate.
- 21. A formulation as claimed in claim 20 wherein the propellant is 1,1,1,2-tetrafluoroethane.
- 22. A formulation as claimed in claim 21 wherein the surfactant is lecithin.
- 23. A formulation as claimed in claim 1 wherein the medicament is beclomethasone dipropionate.
- 24. A formulation as claimed in claim 23 wherein the propellant is 1,1,1,2-tetrafluoroethane.
- 25. A formulation as claimed in claim 24 wherein the surfactant is lecithin.
- 26. An aerosol dispersion formulation consisting essentially of; (i) a hydrogen-containing fluorocarbon or a hydrogen-containing chlorofluorocarbon propellant; (ii) a co-solvent having higher polarity than said propellant, which co-solvent is present in an amount of less than 1% w/w based upon the weight of the propellant; and (iii) a pre-coated medicament in an amount of from 0.005 to 5% w/w, based upon the total weight of the formulation, said pre-coated medicament consisting of a medicament in particulate form, said medicament having a particle size of less than 100 microns and having a dry surface coating of surfactant, which surfactant is present in an amount of from 0.01 to 10% w/w based upon the weight of the medicament and which surfactant has no affinity for said propellant.
- 27. An aerosol dispersion formulation consisting essentially of (i) 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane as propellant; (ii) a co-solvent having higher polarity than said propellant, which co-solvent is present in an amount of less than 1% w/w based upon the weight of the propellant; and (iii) a pre-coated medicament in an amount of from 0.005 to 5% w/w, based upon the total weight of the formulation, said pre-coated medicament consisting of a medicament in particulate form, said medicament having a particle size of less than 100 microns and having a dry surface coating of surfactant, which surfactant is present in an amount of from 0.01 to 10% w/w based upon the weight of the medicament and which surfactant has no affinity for said propellant.
- 28. A formulation as claimed in claim 1 wherein the medicament is treated with a surfactant to obtain the surfactant-coated particulate medicament prior to dispersion of the surfactant-coated particulate medicament in the propellant to form the aerosol formulation.
- 29. A surface-coated particulate medicament for use in inhalation therapy containing as a surface coating from 0.05 to 5% w/w, relative to the medicament, of a physiologically acceptable surfactant.
- 30. The surface-coated particulate medicament of claim 29 wherein the surfactant is a non-ionic physiologically acceptable surfactant.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9024365 |
Nov 1990 |
GBX |
|
CROSS REFERENCES TO RELATED APPLICATIONS
This application is a file wrapper continuation of Ser. No. 08/305,851, filed Sep. 14, 1994, now abandoned, which is a file wrapper continuation of application Ser. No. 08/039,424, filed Apr. 29, 1993, now abandoned, which is a 371 of PCT/GB91/01960, filed Nov. 7, 1991.
US Referenced Citations (9)
Foreign Referenced Citations (7)
Number |
Date |
Country |
0 372 777 |
Jun 1990 |
EPX |
452384 |
Oct 1993 |
EPX |
1719443 |
Apr 1972 |
DEX |
3905726 |
Aug 1990 |
DEX |
977934 |
Dec 1994 |
GBX |
8604233 |
Jul 1986 |
WOX |
9007333 |
Jul 1990 |
WOX |
Non-Patent Literature Citations (7)
Entry |
Voigt, Manual of Pharmaceutical Technology, 5th Ed., pp. 359-370 (1984). |
Lachman et al. Eds. The Theory and Practice of Industrial Pharmacy, 2nd Ed., pp. 270 and 276-280 (1976). |
Evans et al., Journal of Pharmacy and Pharmacology, 40 7P, (1988). |
Clarke et al. Journal of Pharmacy and Pharmacology, Supplement 42, 9P, (1990). |
"Hoechst on the substitution for FCKW" Position: Hoechst Chemikalien, (1990). |
Meirion Jones, New Scientist, pp. 56-60, May 26, (1988). |
Lachman et al., Eds., The Theory and Practice of Industrial Pharmacy, 3rd Ed., pp. 603-604, (1986). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
305851 |
Sep 1994 |
|
Parent |
039424 |
|
|